Search
forLearn
5 / 801 resultslearn Mesotherapy
technique to inject very small amounts of beneficial chemicals into the scalp
learn Pygeum Bark
learn Ginseng
learn Paeonia suffruticosa root
Research
5 / 1000+ resultsresearch 팔정산약침이 실험적으로 유발된 전립선 비대증 Rat에 미치는 영향
Paljeong-san pharmacopuncture helps reduce symptoms of enlarged prostate by slowing tissue growth.
research Corn silk extract improves benign prostatic hyperplasia in experimental rat model
Corn silk extract helps reduce prostate enlargement symptoms.
research Anti-inflammatory Effects in LPS-treated RAW 264.7 Cells and the Influences on Drug Metabolizing Enzyme Activities by the Traditional Herbal Formulas, Yongdamsagan-Tang and Paljung-san
The traditional herbal formulas Yongdamsagan-Tang and Paljung-san, along with the drug finasteride, can reduce inflammation and may work together without affecting each other's effectiveness against benign prostatic hyperplasia.
research A Case Study of Androgenetic Alopecia in woman Improved by Pharmacopuncture Therapy and Needle-embedding Therapy
The woman's hair loss improved significantly with pharmacopuncture and needle-embedding therapy.
research A Case Study of Androgenetic Alopecia in woman Improved by Pharmacopuncture Therapy and Needle-embedding Therapy
The woman's hair loss improved significantly after treatment with acupuncture, pharmacopuncture, and needle-embedding therapy.
Community Join
5 / 1000+ resultscommunity Pelage have presented only phase 2a. The rest of phase 2 for PP405 will be presented at a later medical meeting
PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.
community Quote from Pelage (PP-405) Spokesperson...
Pelage is developing a topical hair follicle stem cell therapy, PP405, for non-scarring alopecias like androgenetic alopecia, with Phase III trials planned and a potential market launch by 2027. The treatment may not require continuous use after initial regrowth.
community New company created by Dr. Kang-Yell Choi to commercialize PTD-DBM therapy
PTD-DBM therapy for hair loss is being developed by Dr. Kang-Yell Choi, with human testing planned in South Korea. Some clinics in the U.S. offer PTD-DBM/valproic acid therapy, but it hasn't completed trials yet.
community Approve PP405 quickly you coward
Pelage Pharmaceuticals is developing PP405, a topical treatment for hair growth, currently in Phase 2a trials. There is skepticism about the company's claims, and no fast-tracking approval timeline has been detailed.
community Pelage Pharmaceutical Raises 120 million to continue PP405 Research. Link inside.
Pelage Pharmaceutical raised $120 million to continue research on PP405, a promising hair loss treatment that showed a 20% increase in hair density in 31% of men during a Phase 2a trial. The treatment was well-tolerated, with no systemic absorption, and Phase 3 trials are planned for 2026.